JZUS - Journal of Zhejiang University SCIENCE

Full Text: <528>

CLC number:

On-line Access: 2022-10-12

Received: 2022-04-30

Revision Accepted: 2022-08-10

Crosschecked: 2022-10-13

Cited: 0

Clicked: 508

Citations: Bibtex RefMan EndNote GB/T7714

ORCID:

Ai-fu Lin

https://orcid.org/0000-0002-3968-3617

Journal of Zhejiang University SCIENCE B

Accepted manuscript available online (unedited version)

Cancer immunotherapy: an evolving paradigm

Author(s): Aifu LIN
Affiliation(s): MOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences, Zhejiang University, Hangzhou 310058, China; more
Corresponding email(s): linaifu@zju.edu.cn
Key Words:

Share this article to： More \|Next Paper >>>

Aifu LIN. Cancer immunotherapy: an evolving paradigm[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2210001

@article{title="Cancer immunotherapy: an evolving paradigm",
author="Aifu LIN",
journal="Journal of Zhejiang University Science B",
year="in press",
publisher="Zhejiang University Press & Springer",
doi="https://doi.org/10.1631/jzus.B2210001"
}

%0 Journal Article
%T Cancer immunotherapy: an evolving paradigm
%A Aifu LIN
%J Journal of Zhejiang University SCIENCE B
%P 791-792
%@ 1673-1581
%D in press
%I Zhejiang University Press & Springer
doi="https://doi.org/10.1631/jzus.B2210001"

TY - JOUR
T1 - Cancer immunotherapy: an evolving paradigm
A1 - Aifu LIN
J0 - Journal of Zhejiang University Science B
SP - 791
EP - 792
%@ 1673-1581
Y1 - in press
PB - Zhejiang University Press & Springer
ER -
doi="https://doi.org/10.1631/jzus.B2210001"

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract:

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]ChenJ, ChenJ, WangL, 2022. Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor infiltrating immunocytes. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):812-822.

[2]FangL, QiH, WangP, et al., 2022. UPF1 increases amino acid levels and promotes cell proliferation in lung adenocarcinoma via the eIF2α-ATF4 axis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):863-875.

[3]GaoZR, LingXY, ShiCY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.

[4]GuTN, ZhuM, HuangH, et al., 2022. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):793-811.

[5]KongDL, YangTT, GengJ, et al., 2022. Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):876-880.

[6]QuL, HeXY, TangQ, et al., 2022. Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):‍844-862.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

- Go to

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference